Heart failure is one of the most prevalent diseases and the most frequent cause of hospitalisation in people over 65 years.
Classical treatment for heart failure was pharmacotherapy, but the emergence of cardiac resynchronization devices allowed the reduction of overall mortality, as well as, heart failure mortality and number of hospital admisions associated with the disease.
There are two types of cardiac resynchronization devices: conventional and one associated with a defibrillator. This second type offers the additional theoretical advantages of preventing arrhythmic events and sudden cardiac death.
The aim of our study is to determine the cost-effectiveness of cardiac resynchronization therapy (CRT) compared with drug therapy, based on full economic evaluation studies in the literature, as well as the development of our own economic evaluation for the Spanish healthcare setting.